UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed b	y the l	Registrant $oxin $ Filed by a Party other than the Registrant $oxin $
Check	the ap	propriate box:
	Preli	iminary Proxy Statement
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))	
	Defi	nitive Proxy Statement
\boxtimes	Defi	nitive Additional Materials
	Soli	citing Material Pursuant to § 240.14a-12
		ZIOPHARM Oncology, Inc.
		(Name of Registrant as Specified in Its Charter)
Daymo	nt of E	(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Filing Fee (Check the appropriate box):
_		
\boxtimes		ee required.
		computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
	(1)	Title of each class of securities to which transaction applies:
	(2)	Aggregate number of securities to which transaction applies:
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
	(4)	Proposed maximum aggregate value of transaction:
	(5)	Total fee paid:
	Fee p	paid previously with preliminary materials:
		k box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. ify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
	(1)	Amount previously paid:
	(2)	Form, Schedule or Registration Statement No.:
	(3)	Filing Party:
	(4)	Date Filed:

*** Exercise Your Right to Vote ***

Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to Be Held on September 18, 2018

ZIOPHARM ONCOLOGY, INC.

Meeting Information

Meeting Type: Annual Meeting For holders as of: July 23, 2018

Date: September 18, 2018 Time: 10:00 AM EDT

Location: 1114 Avenue of the Americas

46th Floor

New York, NY 10036-7798

ZIOPHARM ONCOLOGY, INC. ATTN: CORPORATE SECRETARY ONE FIRST AVENUE, PARRIS BLDG #34 THIRD FLOOR, NAVY YARD PLAZA BOSTON, MA 02129 You are receiving this communication because you hold shares in the above named company.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

See the reverse side of this notice to obtain proxy materials and voting instructions.

— Before You Vote —

How to Access the Proxy Materials

Proxy Materials Available to VIEW or RECEIVE:

1. Notice & Proxy Statement 2. Form 10-K

How to View Online:

How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

1) BY INTERNET: www.proxyvote.com 2) BY TELEPHONE: 1-800-579-1639

3) BY E-MAIL*: sendmaterial@proxyvote.com

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before September 05, 2018 to facilitate timely delivery.

— How To Vote —

Please Choose One of the Following Voting Methods

Vote In Person: Many stockholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

Voting items

The Board of Directors recommends you vote FOR the following:

1. Election of Directors

Nominees

01 James A. Cannon

02 Elan Z. Ezickson

03 Randal J. Kirk

04 Douglas W. Pagan

05 Scott Tarriff

The Board of Directors recommends you vote FOR proposals 2, 3 and 4.

- 2. To ratify the appointment of RSM US LLP as the Company's independent registered public accounting firm for 2018
- To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement
- To approve an amendment to the Company's 2012 Equity Incentive Plan, as amended, to increase the number of shares of common stock reserved for issuance thereunder from 9,000,000 shares to 14,000,000 shares

NOTE: To transact any other business as may properly come before the meeting or any adjournments or postponements thereof.